Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis

Not Applicable

Completed

• Conditions: Meningitis, Cryptococcal; HIV Infections

• Registration Number: NCT00002040
• Lead Sponsor: Pfizer

Brief Summary

To evaluate the safety and effectiveness of fluconazole as an intravenous dose as initial treatment for acute cryptococcal meningitis followed by oral therapy in AIDS and non-AIDS patients. Both newly diagnosed and relapsed patients are eligible. The effectiveness of maintenance fluconazole therapy in sustaining a clinical cure in AIDS patients will also be evaluated.

Detailed Description

Not available

Study Timeline

• Status Verified: 1990-02
• Study First Submitted: 1999-11-02
• Study First Submitted QC: 2001-08-30
• Study First Posted: 2001-08-31
• Last Update Submitted: 2005-06-23
• Last Update Posted: 2005-06-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: Not specified

Trial Locations

Locations (5)

Cook County Hosp; 🇺🇸 Chicago, Illinois, United States

Summitt Med Ctr / San Francisco Gen Hosp; 🇺🇸 Oakland, California, United States

Cornell Univ Med Ctr; 🇺🇸 New York, New York, United States

Buckley Braffman Stern Med Associates; 🇺🇸 Philadelphia, Pennsylvania, United States

SUNY / Health Sciences Ctr at Brooklyn; 🇺🇸 Brooklyn, New York, United States